JP4676536B2 - Ｈｉｖインテグラーゼ阻害剤の薬物動態の改善方法 - Google Patents

Ｈｉｖインテグラーゼ阻害剤の薬物動態の改善方法 Download PDF

Info

Publication number
JP4676536B2
JP4676536B2 JP2008548784A JP2008548784A JP4676536B2 JP 4676536 B2 JP4676536 B2 JP 4676536B2 JP 2008548784 A JP2008548784 A JP 2008548784A JP 2008548784 A JP2008548784 A JP 2008548784A JP 4676536 B2 JP4676536 B2 JP 4676536B2
Authority
JP
Japan
Prior art keywords
hiv
pharmaceutically acceptable
acceptable salt
compound
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008548784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009525265A (ja
JP2009525265A5 (enExample
Inventor
カーニー、ブライアン、ピー．
敦之 掛江
功 川口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of JP2009525265A publication Critical patent/JP2009525265A/ja
Publication of JP2009525265A5 publication Critical patent/JP2009525265A5/ja
Application granted granted Critical
Publication of JP4676536B2 publication Critical patent/JP4676536B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008548784A 2005-12-30 2006-12-29 Ｈｉｖインテグラーゼ阻害剤の薬物動態の改善方法 Active JP4676536B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75503905P 2005-12-30 2005-12-30
US75663106P 2006-01-06 2006-01-06
US76390106P 2006-02-01 2006-02-01
PCT/US2006/049668 WO2007079260A1 (en) 2005-12-30 2006-12-29 Methods for improving the pharmacokinetics of hiv integrase inhibitors

Publications (3)

Publication Number Publication Date
JP2009525265A JP2009525265A (ja) 2009-07-09
JP2009525265A5 JP2009525265A5 (enExample) 2010-03-04
JP4676536B2 true JP4676536B2 (ja) 2011-04-27

Family

ID=38016698

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008548784A Active JP4676536B2 (ja) 2005-12-30 2006-12-29 Ｈｉｖインテグラーゼ阻害剤の薬物動態の改善方法

Country Status (16)

Country Link
US (1) US20070219243A1 (enExample)
EP (2) EP1976517A1 (enExample)
JP (1) JP4676536B2 (enExample)
KR (3) KR20160074018A (enExample)
CN (1) CN104069108A (enExample)
AP (1) AP2702A (enExample)
AU (1) AU2006332664B2 (enExample)
BR (1) BRPI0620865A2 (enExample)
CA (2) CA2635468C (enExample)
EA (2) EA018544B1 (enExample)
HR (1) HRP20080313A2 (enExample)
IL (1) IL192208A (enExample)
NO (1) NO20083333L (enExample)
NZ (1) NZ569576A (enExample)
SG (2) SG170796A1 (enExample)
WO (1) WO2007079260A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EP2118082B1 (en) 2007-02-23 2014-10-01 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CA2692101A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and a compound that inhibits a ugt pathway or ugt metabolism
AU2008270634B2 (en) * 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
GB2470494B (en) * 2008-01-17 2012-08-08 Univ Holy Ghost Duquesne Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS
EA032868B1 (ru) * 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
MX344879B (es) 2012-12-21 2017-01-11 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
LT3019503T (lt) 2013-07-12 2017-11-27 Gilead Sciences, Inc. Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui
NO2865735T3 (enExample) 2013-07-12 2018-07-21
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (enExample) 2014-06-20 2018-06-23
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
LT3236972T (lt) 2014-12-26 2021-11-10 Emory University Antivirusiniai n4-hidroksicitidino dariniai
CA2980362C (en) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
KR102606625B1 (ko) 2015-11-09 2023-11-27 길리애드 사이언시즈, 인코포레이티드 인간 면역결핍 바이러스의 치료를 위한 치료 조성물
LT3706762T (lt) 2017-12-07 2024-12-27 Emory University N4-hidroksicitidinas ir jo dariniai bei susiję naudojimo prieš virusus būdai

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
EP1090914B1 (en) * 1992-12-29 2003-01-02 Abbott Laboratories Retroviral protease inhibiting compounds
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
CA2371109C (en) * 1999-06-04 2011-04-26 Laman A. Alani Improved pharmaceutical formulations
US6541515B2 (en) * 2000-08-09 2003-04-01 Merck & Co., Inc. HIV integrase inhibitors
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
AR037797A1 (es) * 2001-12-12 2004-12-01 Tibotec Pharm Ltd Combinacion de inhibidores de proteasa dependientes del citocromo p450
AU2003301439A1 (en) 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
SI1564210T1 (sl) * 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
CA2513141A1 (en) * 2003-01-27 2004-08-12 Pfizer Inc. Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use
JP2006528694A (ja) 2003-05-13 2006-12-21 スミスクライン ビーチャム コーポレーション ナフチリジンインテグラーゼインヒビター
WO2005113509A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US8633219B2 (en) 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
EP1891089B1 (en) * 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
CN105503721A (zh) * 2006-09-12 2016-04-20 吉里德科学公司 制备整合酶抑制剂的方法和中间体
CA2692101A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and a compound that inhibits a ugt pathway or ugt metabolism
AU2008270634B2 (en) * 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa

Also Published As

Publication number Publication date
AP2008004522A0 (en) 2008-06-30
CA2635468A1 (en) 2007-07-12
KR20140082858A (ko) 2014-07-02
WO2007079260A9 (en) 2007-08-30
JP2009525265A (ja) 2009-07-09
EA200801619A1 (ru) 2008-10-30
SG170795A1 (en) 2011-05-30
CA2847871C (en) 2016-07-26
KR20160074018A (ko) 2016-06-27
CA2847871A1 (en) 2007-07-12
EA201201496A1 (ru) 2013-07-30
HRP20080313A2 (en) 2008-11-30
AU2006332664B2 (en) 2013-03-14
EA018544B1 (ru) 2013-08-30
EP1976517A1 (en) 2008-10-08
SG170796A1 (en) 2011-05-30
CA2635468C (en) 2016-08-09
NZ569576A (en) 2011-09-30
IL192208A0 (en) 2009-02-11
EP2308490A1 (en) 2011-04-13
AU2006332664A1 (en) 2007-07-12
AP2702A (en) 2013-07-23
WO2007079260A1 (en) 2007-07-12
US20070219243A1 (en) 2007-09-20
IL192208A (en) 2013-10-31
BRPI0620865A2 (pt) 2011-11-29
CN104069108A (zh) 2014-10-01
NO20083333L (no) 2008-09-29
KR20080081358A (ko) 2008-09-09
KR101524165B1 (ko) 2015-06-01

Similar Documents

Publication Publication Date Title
JP4676536B2 (ja) Ｈｉｖインテグラーゼ阻害剤の薬物動態の改善方法
JP5769763B2 (ja) 治療用組成物およびその使用
US20190358240A1 (en) Hiv treatment formulation of atazanavir and cobicistat
KR102722927B1 (ko) 조합물 및 이의 용도 및 치료
US20090233964A1 (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors
US10786518B2 (en) Compositions and methods of treating HIV
MX2012011415A (es) Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
AU2013203476B2 (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors
HK1156259A (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors
CN101336107A (zh) 改善hiv整合酶抑制剂的药物动力学的方法
HK40002830B (en) Hiv treatment formulation of atazanavir and cobicistat
ULC et al. Pr MYLAN-ATAZANAVIR
HK1165277A (en) Combinations of a pyrimidine containing nnrti with rt inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100118

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20100118

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20100210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101007

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110105

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110127

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140204

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4676536

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250